NEUmiRNA Therapeutics, a leading biotechnologycompany pioneering innovative RNA-based therapeutics, proudly announces thereception of a grant from The Michael J. Fox Foundation for Parkinson’s Research(MJFF) that will fund NEUmiRNA's groundbreaking work in advancing diseasemodifying RNA therapies for Parkinson’s disease (PD). The $650.000 grant willpropel the preclinical development of selected antisense oligonucleotidesdesigned to selectively inhibit a micro-RNA at the center of PD pathophysiology.
In a synergistic industry-academia collaboration, NEUmiRNA will partner with MotacNeuroscience and the Center for RNA Medicine at Aalborg University to harnesstheir collective expertise in developing cutting-edge RNA-based therapeutics. Thesynergy between NEUmiRNA's innovative approach, Motac Neuroscience'sextensive experience in preclinical models for neurodegenerative diseases, and theresearch excellence of the Center for RNA Medicine at Aalborg University enablesaccelerated progress towards impactful treatments for PD.
Prof Janine Erler, grant PI and CEO of NEUmiRNA Therapeutics, commented, "Thisgrant is a key milestone in our mission to revolutionize PD treatment. Receiving agrant from The Michael J. Fox Foundation will help translate groundbreakingdiscoveries in RNA biology into transformational therapies for PD patients."
NEUmiRNA's proprietary platform focuses on the development of RNA-basedtherapeutics that modulate disease pathways, presenting a novel avenue fortreating neurodegenerative diseases rather than only alleviating symptoms.
The Michael J. Fox Foundation's funding support underscores the importance ofcollaborative innovation in driving progress toward new effective therapies for PD.This grant not only bolsters NEUmiRNA's research endeavors, but also reaffirms theFoundation's commitment to accelerating breakthroughs in Parkinson’s research.
Neumirna Receives $650,000 Grant from The Michael J. Fox Foundation to Advance RNA Therapies for Parkinson’s Disease
The project, conducted in collaboration with Motac Neuroscience and the Center for RNA Medicine at Aalborg University, aims to accelerate the development of disease-modifying treatments targeting microRNAs in Parkinson’s disease.
.png)
.svg)
